World leader in breast cancer screening celebrates start of Breast
Cancer Awareness Month, releases new survey results on breast density
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Hologic, Inc. (Nasdaq: HOLX) announced today that Nancy G. Brinker,
global cancer advocate, Hologic consultant and founder of Susan G.
Komen, and Krystal Barter, author and founder of Australian nonprofit
Pink Hope, will join Steve MacMillan, the Company’s Chairman, President
and Chief Executive Officer, and selected employees to ring the Nasdaq
Opening Bell for the 13th consecutive year on October 1 to
mark the start of Breast Cancer Awareness Month.
In addition to appearing at the Nasdaq MarketSite, Hologic will
recognize Breast Cancer Awareness Month by announcing the results from
their recent survey, conducted online by The Harris Poll among over
1,000 U.S. women, designed to highlight the need for education about
breast density and the effect it has on breast cancer screening and
cancer detection. Most notably, the survey found 64 percent of U.S.
women do not know that the density of a woman’s breasts affects her risk
of developing breast cancer; more than two-thirds of U.S. women (68%) do
not know their breast density score; and just 36 percent of women have
discussed their breast density with a medical professional.1
Grammy award-winning artist, breast cancer survivor and Genius exam
spokesperson Sheryl Crow will educate women on this important topic
throughout the month via traditional, digital and social media.
Hologic is the pioneer behind the Genius™ 3D Mammography™ exam, the
first breast tomosynthesis exam approved by the FDA in 2011. The Genius
exam detects 20-65 percent more invasive breast cancers and is the only
mammogram approved by the FDA as superior for women with dense breasts
compared to 2D alone.2,3 Nearly half of women between the
ages of 40 to 74 have dense breasts, which can make it difficult to
detect breast cancer during annual screenings.4,5 Density is
only identifiable on a mammogram or other imaging modalities, and
reflects how much fibrous or glandular tissue is in the breast. Women
with dense breasts often require additional imaging, which can result in
increased patient anxiety and unnecessary costs. Perhaps most important,
women with very dense breasts are four to five times more likely to
develop breast cancer than women with less dense breasts.6,7
“We are thrilled to once again ring in Breast Cancer Awareness Month,
and share important information about breast density,” said MacMillan.
“Since bringing the Genius exam to market in 2011, we have worked
tirelessly to ensure that women all over the world have better access to
this superior screening option, and we will continue until the Genius
exam is available to every woman, everywhere.
“I’m honored to be joined by Ms. Brinker and Ms. Barter, two powerful
advocates who have made a remarkable impact on millions of people over
the years. Their dedication to educating and supporting women across the
globe is unwavering and inspiring, and I am proud to stand beside them
to ring in the start of Breast Cancer Awareness Month.”
In the past year, Hologic has introduced a number of new innovations on
its 3Dimensions™ Mammography System, now the fastest, highest resolution
breast tomosynthesis system ever.8 With these innovations,
the system now provides higher resolution 3D™ images for radiologists,
enhanced workflow for technologists, and a more comfortable mammography
experience, with low-dose options, for patients.
The Genius™3D Mammography™exam (also known as
the Genius™ exam) is only available on a Hologic®3D
Mammography™system. It consists of a 2D and 3D™image
set, where the 2D image can be either an acquired 2D image or a 2D image
generated from the 3D™image set. There are more than 5,000
Hologic 3D Mammography™ systems in use in the U.S. alone, so women have
convenient access to the Genius exam. To learn more about the Genius
exam, visit http://www.Genius3DNearMe.com.
Webcast Information
Hologic’s participation in the Nasdaq opening bell ceremony will be
aired live at https://new.livestream.com/NASDAQ/live
and with closed captioning on the Nasdaq MarketSite tower in Times
Square. A video of the ceremony will be archived for one year on the
Nasdaq site.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily
focused on improving women’s health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic, 3D, 3D Mammography, 3Dimensions, Genius, and The Science of
Sure are trademarks and/or registered trademarks of Hologic, Inc.,
and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.
This information is not intended as a product solicitation or promotion
where such activities are prohibited. For specific information on what
products are available for sale in a particular country, please contact
a local Hologic sales representative or write to womenshealth@hologic.com.
1 HOLOGIC survey, conducted online by The Harris Poll August
14-16, 2018 among 1,155 U.S. women. This online survey is not based on a
probability sample and therefore no estimate of theoretical sampling
error can be calculated. For complete survey methodology, including
weighting variables and subgroup sample sizes, please contact Jane Mazur.
2 Results from Friedewald, SM, et al. "Breast cancer
screening using tomosynthesis in combination with digital mammography." JAMA
311.24 (2014): 2499-2507; a multi-site (13), non-randomized,
historical control study of 454,000 screening mammograms investigating
the initial impact the introduction of the Hologic Selenia® Dimensions®
on screening outcomes. Individual results may vary. The study found an
average 41% increase and that 1.2 (95% CI: 0.8-1.6) additional invasive
breast cancers per 1,000 screening exams were found in women receiving
combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D
Mammography™ System versus women receiving 2D FFDM mammograms only.
3 FDA submissions P080003, P080003/S001, P080003/S004,
P080003/S005.
4 Ho JM, Jafferjee N, Covarrubias GM, Ghesani M, Handler B.
Dense breasts: a review of reporting legislation and available
supplemental screening options. AJR Am J Roentgenol. 203(2):449-56, 2014.
5 Sprague BL, Gangnon RE, Burt V, et al. Prevalence of
mammographically dense breasts in the United States. J Natl Cancer Inst.
106(10), 2014.
6 Boyd NF, Guo H, Martin LJ, et al. Mammographic density and
the risk and detection of breast cancer. N Engl J Med. 356(3):227-36,
2007.
7 Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic
breast density and subsequent risk of breast cancer in postmenopausal
women according to tumor characteristics. J Natl Cancer Inst.
103(15):1179-89, 2011.
8 Data on file
View source version on businesswire.com:
https://www.businesswire.com/news/home/20180927005725/en/
Media Contact:
Hologic, Inc.
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
or
Nasdaq
Emily
Pan
646.441.5120
or
Investor
Contact:
Hologic, Inc.
Michael Watts
858.410.8588
michael.watts@hologic.com
Source: Hologic, Inc.